BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BGM1812 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BGM1812\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07918625-201@assetmemo.bio
DTSTAMP:20261121T005850Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:BGM1812: Phase 2 readout est. (NCT07918625)
DESCRIPTION:BGM1812\, phase 2\, Obesity.\nStudy: A Study to Evaluate Effica
 cy and Safety of BGM1812 Injection in Overweight or Obese Participants Wit
 hout Diabetes\nEstimated primary completion: 1 August 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/bgm1812#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07918625
URL:https://assetmemo.bio/drug/bgm1812#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
